Pneumocystis Prophylaxis

Pneumocystis Prophylaxis is a clinical pharmacological intervention classified as a preventive antimicrobial strategy that specifically targets the prevention of Pneumocystis jirovecii pneumonia in immunocompromised recipients of hematopoietic stem cell transplantation through targeted antimicrobial suppression during periods of sustained immune deficiency.

684

Publications

37.2K

Citations

3.5K

Authors

1.1K

Institutions

Publications per year

2017–2026

83

Authors

3.5K

  1. WT
    Walter T. Hughes

    St. Jude Children's Research Hospital, United States

    20 publications · 1.9K citations

    17

    h-index

  2. DM
    Dianne M. Finkelstein

    Massachusetts General Hospital, United States

    9 publications · 2.1K citations

    9

    h-index

  3. PM
    Philippe M. Hauser

    University Hospital of Lausanne, Switzerland

    8 publications · 747 citations

    8

    h-index

  4. MS
    Marilyn S. Bartlett

    Indiana University – Purdue University Indianapolis, United States

    7 publications · 657 citations

    7

    h-index

  5. AJ
    Alfred J. Saah

    Johns Hopkins University, United States

    7 publications · 1.8K citations

    7

    h-index

1–5 of 3.5K

Venues

  1. PubMed

    Repository · 63 publications · 2.7K citations

    31

    h-index

  2. Clinical Infectious Diseases

    CID · 35 publications · 2K citations

    24

    h-index

  3. AIDS

    29 publications · 1.4K citations

    22

    h-index

  4. Antimicrobial Agents and Chemotherapy

    AAC · 36 publications · 1.4K citations

    21

    h-index

  5. New England Journal of Medicine

    NEJM · 19 publications · 5.8K citations

    19

    h-index

1–5